BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo.

Article Details

Citation
Copy to clipboard

Kalanaky S, Hafizi M, Fakharzadeh S, Vasei M, Langroudi L, Janzamin E, Hashemi SM, Khayamzadeh M, Soleimani M, Akbari ME, Nazaran MH

BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo.

Drug Des Devel Ther. 2015 Dec 30;10:59-70. doi: 10.2147/DDDT.S89694. eCollection 2016.

PubMed ID
26766901 [ View in PubMed
]
Abstract

PURPOSE: In spite of all the efforts and researches on anticancer therapeutics, an absolute treatment is still a myth. Therefore, it is necessary to utilize novel technologies in order to synthesize smart multifunctional structures. In this study, for the first time, we have evaluated the anticancer effects of BCc1 nanocomplex by vitro and in vivo studies, which is designed based on the novel nanochelating technology. METHODS: Human breast adenocarcinoma cell line (MCF-7) and mouse embryonic fibroblasts were used for the in vitro study. Antioxidant potential, cell toxicity, apoptosis induction, and CD44 and CD24 protein expression were evaluated after treatment of cells with different concentrations of BCc1 nanocomplex. For the in vivo study, mammary tumor-bearing female Balb/c mice were treated with different doses of BCc1 and their effects on tumor growth rate and survival were evaluated. RESULTS: BCc1 decreased CD44 protein expression and increased CD24 protein expression. It induced MCF-7 cell apoptosis but at the same concentrations did not have negative effects on mouse embryonic fibroblasts viability and protected them against oxidative stress. Treatment with nanocomplex increased survival and reduced the tumor size growth in breast cancer-bearing balb/c mice. CONCLUSION: These results demonstrate that BCc1 has the capacity to be assessed as a new anticancer agent in complementary studies.

DrugBank Data that Cites this Article

Drugs